Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Cariou

Showing results (21-30 of 311) with videos related to

Pageof 32
Sort By:
Med (New York, N.Y.)|August 9, 2025
Obicetrapib and CETP inhibition: An exception to the rule?Bertrand Cariou, Philippe Moulin
Current Opinion in Lipidology|March 20, 2018
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studiesLaurent Yvan-Charvet, Bertrand Cariou
Journal of the American Heart Association|November 21, 2015
PCSK9 Inhibition: Does Lipoprotein Size Matter?Karim Si-Tayeb, Bertrand Cariou
Circulation|May 6, 2015
Letter from Le May and Cariou regarding article, "Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms"Cedric Le May, Bertrand Cariou
La Revue Du Praticien|April 2, 2011
[Dyslipidemia]Maëlle Le Bras, Bertrand Cariou
Trends in Biochemical Sciences|August 2, 2008
PCSK9 and LDL cholesterol: unravelling the target to design the bulletPhilippe Costet, Michel Krempf, Bertrand Cariou
European Journal of Endocrinology|October 25, 2013
Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolismBruno Vergès, Thomas Walter, Bertrand Cariou
Journal of Hepatology|September 19, 2024
Reply to "The association between primary hypobetalipoproteinemia and hepatic diseases: evidence from genetic studies"Antoine Rimbert, Matthieu Wargny, Bertrand Cariou
Biochemical Pharmacology|December 17, 2011
DPP-4 inhibitors in the treatment of type 2 diabetesHélène Duez, Bertrand Cariou, Bart Staels
Trends in Endocrinology and Metabolism: TEM|April 20, 2012
Thiazolidinediones and PPARγ agonists: time for a reassessmentBertrand Cariou, Bernard Charbonnel, Bart Staels
Pageof 32

Showing results (21-30 of 311) with videos related to

Sort By:
Pageof 32
Med (New York, N.Y.)|August 9, 2025
Obicetrapib and CETP inhibition: An exception to the rule?Bertrand Cariou, Philippe Moulin
Current Opinion in Lipidology|March 20, 2018
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studiesLaurent Yvan-Charvet, Bertrand Cariou
Journal of the American Heart Association|November 21, 2015
PCSK9 Inhibition: Does Lipoprotein Size Matter?Karim Si-Tayeb, Bertrand Cariou
Circulation|May 6, 2015
Letter from Le May and Cariou regarding article, "Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms"Cedric Le May, Bertrand Cariou
La Revue Du Praticien|April 2, 2011
[Dyslipidemia]Maëlle Le Bras, Bertrand Cariou
Trends in Biochemical Sciences|August 2, 2008
PCSK9 and LDL cholesterol: unravelling the target to design the bulletPhilippe Costet, Michel Krempf, Bertrand Cariou
European Journal of Endocrinology|October 25, 2013
Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolismBruno Vergès, Thomas Walter, Bertrand Cariou
Journal of Hepatology|September 19, 2024
Reply to "The association between primary hypobetalipoproteinemia and hepatic diseases: evidence from genetic studies"Antoine Rimbert, Matthieu Wargny, Bertrand Cariou
Biochemical Pharmacology|December 17, 2011
DPP-4 inhibitors in the treatment of type 2 diabetesHélène Duez, Bertrand Cariou, Bart Staels
Trends in Endocrinology and Metabolism: TEM|April 20, 2012
Thiazolidinediones and PPARγ agonists: time for a reassessmentBertrand Cariou, Bernard Charbonnel, Bart Staels
Pageof 32